74 related articles for article (PubMed ID: 2604916)
1. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity.
Ogden JR; Leung K; Kunda SA; Telander MW; Avner BP; Liao SK; Thurman GB; Oldham RK
Mol Biother; 1989; 1(3):170-4. PubMed ID: 2604916
[TBL] [Abstract][Full Text] [Related]
2. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Dillman RO; Johnson DE; Ogden J; Beidler D
Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
[TBL] [Abstract][Full Text] [Related]
3. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
Takahashi H; Adachi K; Yamaguchi F; Teramoto A
Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
Yang HM; Reisfeld RA
Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1189-93. PubMed ID: 3422487
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
8. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies.
Oldham RK; Lewis M; Orr DW; Avner B; Liao SK; Ogden JR; Avner B; Birch R
Mol Biother; 1988; 1(2):103-13. PubMed ID: 3269248
[TBL] [Abstract][Full Text] [Related]
10. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
Dillman RO; Johnson DE; Shawler DL; Koziol JA
Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420
[TBL] [Abstract][Full Text] [Related]
11. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
[TBL] [Abstract][Full Text] [Related]
12. [The selective cytotoxicity of monoclonal antibody conjugated with mitomycin C on human gastric cancer cells].
Liang YY; Wang NQ; Li N; Cui JQ; Dong ZW
Yao Xue Xue Bao; 1989; 24(11):801-6. PubMed ID: 2618675
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity of the conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24.
Mohamed G; Kuzmanoff KM; Stastny JJ; Das Gupta TK
Anticancer Res; 1992; 12(2):529-32. PubMed ID: 1580569
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of the in vitro cytotoxicity of chlorambucil by monoclonal antibodies.
Smyth MJ; Pietersz GA; McKenzie IF
J Immunol; 1986 Nov; 137(10):3361-6. PubMed ID: 3772105
[TBL] [Abstract][Full Text] [Related]
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
17. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
18. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
Shin IS; Jang BS; Danthi SN; Xie J; Yu S; Le N; Maeng JS; Hwang IS; Li KC; Carrasquillo JA; Paik CH
Bioconjug Chem; 2007; 18(3):821-8. PubMed ID: 17375899
[TBL] [Abstract][Full Text] [Related]
19. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited.
Ahmad A; Law KL; Young B; Telander MW; Ogden JR; Leung K
Anticancer Res; 1990; 10(3):837-43. PubMed ID: 2369097
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
